Stock BLUE BLUEBIRD BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights bluebird bio, Inc.

Equities

BLUE

US09609G1004

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.9034 USD +0.87% Intraday chart for bluebird bio, Inc. -6.52% -34.54%
May. 29 Bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024 CI
May. 16 Transcript : Bluebird bio, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy
CI
Bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report
MT
Bluebird bio to Restate Financial Statements; Shares Fall
MT
Gene therapy maker bluebird to restate 2022 financials after accounting error
RE
Bluebird bio Signs Medicaid Agreement for Sickle Cell Disease Therapy with Michigan State
MT
Bluebird bio, Inc. Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
CI
North American Morning Briefing : Investors Await -2-
DJ
Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels
CI
Bluebird bio, Inc. Announces Long-term Follow-up Data From It's Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
CI
Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events
CI
Bluebird Bio, Inc. Announces FDA Approval of LYFGENIA?? (Lovo-Ccel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
CI
US approves two gene therapies for sickle cell disease
RE
Earnings Flash (BLUE) BLUEBIRD BIO Reports Q3 Revenue $12.4M, vs. Street Est of $13.4M
MT
Bluebird bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition
CI
Bluebird bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (BLUE) BLUEBIRD BIO Reports Q2 Revenue $6.9M
MT
Bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease 12 Years and Older with a History of Vaso-Occlusive Events
CI
Earnings Flash (BLUE) BLUEBIRD BIO Reports Q1 Revenue $2.4M, vs. Street Est of $27M
MT
Bluebird bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BLUE Stock
  4. News bluebird bio, Inc.
  5. Highlights